Tissue plasminogen activator modified

Recent applications of HPAEC-PAD are many and varied. A representative list includes quantitation of polyglucose metabolites in plasma of dialysis patients,148 analysis of heat-treated milk,149 carbohydrate content in lipopolysaccharides,150 phosphorylated sugars in tissue samples,151 composition of soybean meal,152 carbohydrate composition of recombinant modified tissue plasminogen activator,153 analysis of cyclization products from an enzyme reaction,154 carbohydrate content of glycoconjugate vaccines,155 and monitoring of patients with rheumatoid arthritis.156... 

Faster acting insulins (Chapter 11) Slow acting insulins (Chapter 11) Modified tissue plasminogen activator (tPA Chapter 12)... 

After this period, there was an accelerated use of animal cells. Namalwa cells (Finter et al., 1991) were used to produce alpha-interferon by Wellcome in 1986. Vero cells (a cell line derived from monkey) were used for anti-rabies vaccine. Hybridomas were considered acceptable for mAb production and the use of genetically modified CHO (Chinese hamster ovary) cells was authorized for the production of tissue plasminogen activator (tPA) by Genentech in 1986. 

Lau, D., Kuzma, G., Wei, C-M., Livingston, D.J., and Hsiung, N. (1987). A modified human tissue plasminogen activator with extended half-life in vivo. Bio/Technology 5,953 958. 

During detailed characterization of a tryptic map of recombinant human tissue plasminogen activator (rtPA), a minor peak was resolved whose mass was not consistent with the expected set of tryptic peptides (L. Keyt and S.-L. Wu, unpublished observation). N-terminal sequence analysis of this fraction showed that it had a sequence containing residues 276-296 of rtPA with Lys-277 present as Hyl. We developed a modified amino acid analysis program capable of detecting hydroxylysine at levels down to 0.05 residues/mol to determine the distribution of Hyl in rtPA as well as in some other proteins derived from mammalian cells. 

Vlakh E, Ostryanina N, Jungbauer A, and Tennikova T. Use of monolithic sorbents modified by directly synthesized peptides for affinity separation of recombinant tissue plasminogen activator (t-PA). J. Biotechnol. 2004 107 275-284. 

Berg DT, Burck PJ, Berg DH, Grinnell BW. 1993. Kringle glycosylation in a modified human tissue plasminogen activator improves functional properties. Blood 81, 1312-1322. 

Neuhaus KL, Feuerer W, Jeep-Tebbe S, Niederer W, Vogt A, Tebbe U. Improved thrombosis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989 14 1566-1569. 

---